Lutetium Lu 177 dotatate is a Synthetic Peptide owned by Advanced Accelerator Applications, and is involved in 67 clinical trials, of which 28 were completed, 33 are ongoing, and 6 are planned. Lutetium Lu 177 dotatate binds to somatostatin receptors with highest affinity for subtype 2 receptors (SSRT2). Upon binding to somatostatin receptor expressing cells, including malignant somatostatin receptor-positive tumors, the compound is internalized. The beta emission from Lu 177 induces cellular damage by formation of free radicals in somatostatin receptor-positive cells and in neighboring cells.

The revenue for Lutetium Lu 177 dotatate is expected to reach a total of $12.9bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Lutetium Lu 177 dotatate NPV Report.

Lutetium Lu 177 dotatate was originated by BioSynthema and is currently owned by Advanced Accelerator Applications. Novartis is the other company associated in development or marketing of Lutetium Lu 177 dotatate.

Lutetium Lu 177 dotatate Overview

Lutetium Lu-177 dotatate or Lutetium (177Lu) oxodotreotide (Lutathera) is a radiolabelled peptide, acts as an antitumor agent.It is formulated as injectable solution for intravenous route of administration. Lutathera is indicated for the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults.

Lutathera is under development for the treatment of  metastatic breast carcinoma, , relapsed or refractory small-cell lung cancer, medullary thyroid cancer, parathyroid carcinoma, pituitary carcinoma, progressive meningioma, refractory or relapsed high-risk neuroblastoma, gastroenteropancreatic neuroendocrine tumors, pheochromocytoma, paraganglioma and metastatic gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs) including inoperable progressive midgut carcinoid, pheochromocytoma, paraganglioma, glioblastoma, recurrent glioblastoma. It is administered through intra-arterial hepatic (IAH) injection.

Novartis Overview

Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.

The company reported revenues of (US Dollars) US$52,877 million for the fiscal year ended December 2021 (FY2021), an increase of 6% over FY2020. In FY2021, the company’s operating margin was 22.1%, compared to an operating margin of 20.3% in FY2020. In FY2021, the company recorded a net margin of 45.4%, compared to a net margin of 16.2% in FY2020. The company reported revenues of US$12,842 million for the third quarter ended September 2022, a decrease of 1.9% over the previous quarter.

Quick View – Lutetium Lu 177 dotatate

Report Segments
  • Innovator (NME)
Drug Name
  • Lutetium Lu 177 dotatate
Administration Pathway
  • Intraarterial
  • Intravenous
Therapeutic Areas
  • Oncology
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.